Target's General Information
Target ID T88304
Target Name DNA [cytosine-5]-methyltransferase 1 (DNMT1)
Synonyms MCMT; M.HsaI; Dnmt1; DNMT; DNA methyltransferase HsaI; DNA MTase HsaI; DNA (cytosine5)methyltransferase 1; DNA (cytosine-5)-methyltransferase 1; CXXCtype zinc finger protein 9; CXXC9; CXXC-type zinc finger protein 9; AIM
Target Type Clinical trial
Gene Name DNMT1
Biochemical Class Methyltransferase
UniProt ID DNMT1_HUMAN
Target's Expression Profile in Disease Related Tissue between Patients and Normal People
Disease Acute myelocytic leukemia
Example drug SGI110 Phase 3 [1], [2], [3]
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.11
Z-score: -0.34
P-value: 6.48E-04
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Myelodysplastic syndromes
Example drug CC-486 Phase 3 [2], [3], [4]
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.09
Z-score: 0.32
P-value: 5.50E-01
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: 0.99
Z-score: 1.58
P-value: 4.61E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Lung cancer
Example drug Antroquinonol Phase 2 [2], [3], [5]
Tissue Lung tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.73
Z-score: 2.22
P-value: 1.56E-81
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: 0.57
Z-score: 2.09
P-value: 5.94E-48
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Sarcoma
Example drug Palifosfamide Phase 2 [2], [3], [6]
Tissue Muscle tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 2.46
Z-score: 4.65
P-value: 0.00E+00
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: 2.56
Z-score: 7.16
P-value: 6.10E-04
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Glioma
Tissue Brainstem tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.71
Z-score: 15.47
P-value: 2.06E-08
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Glioma
Tissue White matter
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.97
Z-score: 2.41
P-value: 1.27E-05
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Target's Expression Profile across Various Tissues of Healthy Individual
References
REF 1 ClinicalTrials.gov (NCT02348489) SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction. U.S. National Institutes of Health.
REF 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 3 NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
REF 4 J Clin Oncol 33, 2015 (suppl, abstr TPS7097).
REF 5 ClinicalTrials.gov (NCT02047344) Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC. U.S. National Institutes of Health.
REF 6 ClinicalTrials.gov (NCT01808534) Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.